Rapid Micro Biosystems (RPID) Cash from Financing Activities (2020 - 2026)
Rapid Micro Biosystems (RPID) reported Cash from Financing Activities of $247000.0 for Q1 2026, down 34.83% on a YoY basis from $379000.0 in Q1 2025, and down 44.24% sequentially from $443000.0 in Q4 2025.
Rapid Micro Biosystems (RPID) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Rapid Micro Biosystems (RPID) has 7 years of Cash from Financing Activities data on file, last reported at $247000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 34.83% year-over-year to $247000.0; the trailing twelve-month figure through Mar 2026 stood at $19.6 million (up 4531.84% YoY), and the FY2025 full-year result was $19.8 million, up 9639.41% from the prior year.
- Cash from Financing Activities declined to $247000.0 in Q1 2026, from $443000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $19.2 million in Q3 2025 to a low of -$298000.0 in Q2 2025.
- A 5-year average of $1.2 million and a median of $87000.0 in 2022 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 31452.46% in 2025, while the deepest fall reached 2880.0% in 2025.
- Tracing RPID's Cash from Financing Activities over 5 years: stood at $87000.0 in 2022, then tumbled by 113.79% to -$12000.0 in 2023, then jumped by 50.0% to -$6000.0 in 2024, then surged by 7483.33% to $443000.0 in 2025, then tumbled by 44.24% to $247000.0 in 2026.
- Business Quant data shows RPID's Cash from Financing Activities at $247000.0 in Q1 2026, $443000.0 in Q4 2025, and $19.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Rapid Micro Biosystems | 90.41 Mn | 80.98 Mn | 371,000.00 | 247,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 247,000.00 |
| Mar 31, 2026 | 247,000.00 |
| Dec 31, 2025 | 443,000.00 |
| Dec 31, 2025 | 443,000.00 |
| Sep 30, 2025 | 19.25 Mn |
| Sep 30, 2025 | 19.25 Mn |
| Jun 30, 2025 | -298,000.00 |
| Jun 30, 2025 | -298,000.00 |
| Mar 31, 2025 | 379,000.00 |
| Mar 31, 2025 | 379,000.00 |
| Dec 31, 2024 | -6,000.00 |
| Dec 31, 2024 | -6,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Mar 31, 2024 | 158,000.00 |
| Mar 31, 2024 | 158,000.00 |
| Dec 31, 2023 | -12,000.00 |
| Dec 31, 2023 | -12,000.00 |